<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02143726</url>
  </required_header>
  <id_info>
    <org_study_id>A091302</org_study_id>
    <secondary_id>U10CA180821</secondary_id>
    <secondary_id>NCI-2014-00623</secondary_id>
    <nct_id>NCT02143726</nct_id>
  </id_info>
  <brief_title>Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer</brief_title>
  <official_title>Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies the effects, good and bad, of using everolimus along&#xD;
      with sorafenib tosylate versus sorafenib tosylate alone in treating patients with advanced&#xD;
      radioactive iodine refractory thyroid cancer. Sorafenib tosylate and everolimus may stop the&#xD;
      growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of&#xD;
      everolimus to sorafenib tosylate may cause more shrinkage of thyroid cancer and may prevent&#xD;
      it from growing but it could also cause more side effects than sorafenib tosylate alone. It&#xD;
      is not yet known whether this treatment with sorafenib tosylate and everolimus is better, the&#xD;
      same, or worse than sorafenib tosylate alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized Phase II trial will compare the progression-free survival (PFS) of sorafenib&#xD;
      and everolimus versus sorafenib alone in patients with radioactive iodine refractory hurthle&#xD;
      cell thyroid cancer. Prior studies have shown that the median PFS is generally around 4.5&#xD;
      months for sorafenib alone in this disease population. It is hoped that the combination of&#xD;
      everolimus and sorafenib can increase the median PFS to at least 9 months. In addition to&#xD;
      PFS, this trial will also compare the confirmed response rate, overall survival (OS) and&#xD;
      adverse event rates between sorafenib and everolimus vs. sorafenib alone. The primary and&#xD;
      secondary objectives for the study are listed below.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To compare the progression free survival between sorafenib and everolimus versus sorafenib&#xD;
      alone in patients with radioactive iodine refractory Hurthle cell thyroid cancer&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      To compare the confirmed response rate, overall survival and adverse event rates between&#xD;
      sorafenib and everolimus versus sorafenib alone.&#xD;
&#xD;
      Treatment will continue until disease progression or unacceptable adverse events. Patients&#xD;
      will be followed for 5 years after randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2014</start_date>
  <primary_completion_date type="Actual">January 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 5 years post-randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed response rate</measure>
    <time_frame>Up to 5 years post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, graded according to Common Terminology Criteria for Adverse Events</measure>
    <time_frame>Up to 5 years post-randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Refractory Hurthle Cell Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over and receive everolimus 10 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sorafenib and everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sorafenib 400 mg PO twice daily and everolimus 5 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>sorafenib</arm_group_label>
    <arm_group_label>sorafenib and everolimus</arm_group_label>
    <other_name>Nexavar ®, BAY 43-9006</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>sorafenib and everolimus</arm_group_label>
    <other_name>RAD001, Afinitor ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:&#xD;
&#xD;
          1. Central pathology review submission - Patients must have 10 representative hematoxylin&#xD;
             and eosin (H&amp;E) stained thyroid tissue slides OR tumor block available for submission&#xD;
             to central pathology review. This review is mandatory prior to registration to confirm&#xD;
             eligibility.&#xD;
&#xD;
          2. Measurable disease - Patients must have measurable disease by Response Evaluation&#xD;
             Criteria In Solid Tumors (RECIST) criteria, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded) as ≥&#xD;
             20 mm with conventional techniques or as ≥ 10 mm with spiral computed tomography (CT)&#xD;
             scan. CT must be performed within 28 days of registration.&#xD;
&#xD;
          3. Radioactive iodine (RAI) - refractory disease defined as 1 or more of the following:&#xD;
&#xD;
               -  Patients who have received greater than 600 mCi of radioactive iodine in their&#xD;
                  lifetime OR&#xD;
&#xD;
               -  RAI-avid metastatic lesion which remained stable in size or progressed despite&#xD;
                  RAI treatment within 9 months of RAI treatment OR&#xD;
&#xD;
               -  10% or more increase in serum thyroglobulin (on thyroid-stimulating hormone&#xD;
                  [TSH]-suppression) within 9 months of RAI treatment OR&#xD;
&#xD;
               -  Index metastatic lesion non-RAI avid on a diagnostic RAI scan OR&#xD;
&#xD;
               -  Presence of fluorodeoxyglucose (FDG) avid metastatic lesions on positron emission&#xD;
                  tomography (PET)/CT scan (standardized uptake values [SUV]max &gt; 5 of any single&#xD;
                  lesion)&#xD;
&#xD;
          4. Progressive disease defined by RECIST criteria ≤ 14 months&#xD;
&#xD;
          5. Patients must have metastatic disease or locally advanced unresectable disease&#xD;
&#xD;
          6. Prior treatment&#xD;
&#xD;
               -  Patients may have received prior radiation therapy to index lesions ≥ 28 days&#xD;
                  prior to registration on this protocol if there has been documented progression&#xD;
                  by RECIST criteria. Prior radiation therapy to the non-index lesions is allowed&#xD;
                  if ≥ 28 days prior to registration on this protocol.&#xD;
&#xD;
               -  Prior RAI therapy is allowed if ≥ 90 days prior to registration on this protocol&#xD;
                  and evidence of progression (as defined above) has been documented in the interim&#xD;
                  (a diagnostic study using &lt; 10 mCi of RAI is not considered RAI therapy).&#xD;
&#xD;
               -  Prior chemotherapy is allowed if ≥ 28 days prior to registration on this&#xD;
                  protocol.&#xD;
&#xD;
               -  Patient may have received any number of prior lines of therapy.&#xD;
&#xD;
               -  No prior use of sorafenib or an mammalian target of rapamycin (mTOR) (including&#xD;
                  phosphoinositide 3-kinase [PI3k] or protein kinase B [AKT]) inhibitor for the&#xD;
                  treatment of thyroid cancer.&#xD;
&#xD;
          7. No history of major surgery ≤ 28 days of registration&#xD;
&#xD;
          8. No history of intracranial brain metastasis&#xD;
&#xD;
          9. Cardiovascular disease. No history of any of the following ≤ 6 months of registration:&#xD;
&#xD;
               -  Myocardial infarction or unstable angina&#xD;
&#xD;
               -  New York Heart Association grade III or greater congestive heart failure&#xD;
&#xD;
               -  Cerebrovascular accident&#xD;
&#xD;
               -  Grade 3 or 4 peripheral ischemia&#xD;
&#xD;
               -  Grade 3 or 4 thromboembolic event&#xD;
&#xD;
         10. Liver disease: No history of the following:&#xD;
&#xD;
               -  Child Pugh Class B or C liver disease&#xD;
&#xD;
               -  &quot;Chronic active&quot; hepatitis defined as:&#xD;
&#xD;
                    1. Hepatitis B surface antigen (HBsAg) &gt; 6 months&#xD;
&#xD;
                    2. Serum hepatitis B virus (HBV) deoxyribonucleic acid (DNA) 20,000 IU/ml (105&#xD;
                       copies/ml), lower values 2,000-20,000 IU/ml (104-105 copies/ml) are often&#xD;
                       seen in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B&#xD;
&#xD;
                    3. Persistent or intermittent elevation in alanine aminotransferase&#xD;
                       (ALT)/aspartate aminotransferase (AST) levels&#xD;
&#xD;
                    4. Liver biopsy showing chronic hepatitis with moderate or severe&#xD;
                       necroinﬂammation&#xD;
&#xD;
         11. No history of gastrointestinal fistula or gastrointestinal perforation &lt; 90 days of&#xD;
             registration.&#xD;
&#xD;
         12. No known history of prolonged QT syndrome&#xD;
&#xD;
         13. No Grade 3 or 4 hypertension (systolic blood pressure [BP] &gt;160 and or diastolic BP &gt;&#xD;
             100) that cannot be controlled with medication prior to registration.&#xD;
&#xD;
         14. Concomitant medications:&#xD;
&#xD;
               -  Chronic concomitant treatment with strong inhibitors of cytochrome P450 3A4&#xD;
                  (CYP3A4) is not allowed on this study. Patients on strong CYP3A4 inhibitors must&#xD;
                  discontinue the drug for 14 days prior to registration on the study.&#xD;
&#xD;
               -  Chronic concomitant treatment with strong CYP3A4 inducers is not allowed.&#xD;
                  Patients must discontinue the drug 14 days prior to the start of study treatment.&#xD;
&#xD;
               -  Patients requiring anticoagulation must be on stable dose of medication prior to&#xD;
                  registration.&#xD;
&#xD;
         15. Not pregnant and not nursing, because this study involves an investigational agent&#xD;
             whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn&#xD;
             are unknown. Therefore, for women of childbearing potential only, a negative serum&#xD;
             pregnancy test done ≤ 7 days prior to registration is required.&#xD;
&#xD;
         16. Age ≥ 18 years&#xD;
&#xD;
         17. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2&#xD;
&#xD;
         18. Required Initial Laboratory Values:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,500/mm^3&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
               -  Creatinine ≤ 1.5 mg/dL OR&#xD;
&#xD;
               -  Calculated creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x upper limits of normal (ULN)&#xD;
&#xD;
               -  Serum glutamic oxaloacetic transaminase (SGOT) (AST) ≤ 2.5 x ULN&#xD;
&#xD;
               -  Fasting serum cholesterol ≤ 300 mg/dL&#xD;
&#xD;
         19. Documentation of disease: Histologic Documentation - Eligible patients must have&#xD;
             histopathologically confirmed Hürthle cell thyroid cancer by central review.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Sherman, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Regional Cancer Center</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Sleepy Hollow</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center-Clinton</name>
      <address>
        <city>Clinton</city>
        <state>North Carolina</state>
        <zip>28328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center-Goldsboro</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne Memorial Hospital</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>North Carolina</state>
        <zip>28546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health System</name>
      <address>
        <city>Janesville</city>
        <state>Wisconsin</state>
        <zip>53547</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

